Centessa Pharmaceuticals (NASDAQ:CNTA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also recently weighed in on CNTA. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Lifesci Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Finally, Wells Fargo & Company started coverage on Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.38.

Centessa Pharmaceuticals Stock Up 0.7%

Shares of CNTA opened at $22.47 on Friday. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $24.57. The company has a market capitalization of $3.01 billion, a PE ratio of -12.55 and a beta of 1.57. The stock has a fifty day simple moving average of $19.90 and a two-hundred day simple moving average of $15.62. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). As a group, equities analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 8,322 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total transaction of $126,744.06. Following the completion of the transaction, the insider directly owned 208,163 shares in the company, valued at $3,170,322.49. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total value of $400,200.00. Following the transaction, the general counsel owned 105,386 shares of the company’s stock, valued at $2,108,773.86. This trade represents a 15.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 205,286 shares of company stock worth $3,993,345 over the last ninety days. Company insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares during the period. Exome Asset Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 17.0% in the 2nd quarter. Exome Asset Management LLC now owns 166,944 shares of the company’s stock valued at $2,194,000 after buying an additional 24,200 shares during the period. Octagon Capital Advisors LP boosted its stake in shares of Centessa Pharmaceuticals by 24.8% in the 2nd quarter. Octagon Capital Advisors LP now owns 1,030,000 shares of the company’s stock valued at $13,534,000 after buying an additional 205,000 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after buying an additional 33,854 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $16,052,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.